DAYQUIL COLD & FLU OTC
Generic Name and Formulations:
Acetaminophen 325mg, dextromethorphan HBr 10mg, phenylephrine HCl 5mg; per liquiCap.
Procter & Gamble Pharmaceuticals
Indications for DAYQUIL COLD & FLU:
Nasal congestion, cough, sore throat, fever, headache, minor aches and pains.
2 caps every 4hrs; max 6 doses/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers. Liquid: sodium-restricted diet.
Analgesic + antitussive + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day. β-blockers may increase the pressor effects of sympathomimetics. Antagonizes antihypertensives.
Nervousness, dizziness, insomnia, hepatotoxicity (overdosage).
LiquiCaps—12, 20, 40, 60; Liq—6oz
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds